About
This guide provides additional context for using the Skyrizi Dosing Calculator, an educational tool designed for healthcare professionals to model standard dosing schedules. It interprets the selections made in the tool to provide a clear, dated administration timeline based on the approved prescribing information for Skyrizi (risankizumab-rzaa).
Outputs
The calculator generates a detailed dosing schedule based on your inputs. Key outputs include:
- Scheduled Dates: Calculates the exact date for each required dose in the selected treatment phase.
- Dose & Administration: Specifies the correct dosage (e.g., 600 mg, 150 mg, 360 mg) and route of administration (Intravenous Infusion or Subcutaneous Injection).
- Phase Context: Clearly labels the output for the selected indication (Crohn’s Disease or PsO/PsA) and treatment phase (Induction or Maintenance).
- Clinical Notes: Provides important reminders, such as the transition from IV induction to SC maintenance for Crohn’s Disease.
How to Use
To generate a dosing schedule, follow these steps:
- 1. Select Indication: Choose either “Plaque Psoriasis (PsO) / Psoriatic Arthritis (PsA)” or “Crohn’s Disease (CD)”.
- 2. Select Treatment Phase: Choose “Induction” for new patients or “Maintenance” for ongoing treatment.
- 3. Enter Dosing Date: If starting Induction, enter the date of the first dose. If calculating Maintenance, enter the date of the last administered dose.
- 4. Calculate: Click “Calculate Schedule” to view the results. The “Reset” button clears all selections.
Dosing Overview
The calculator follows the standard dosing regimens outlined in the full prescribing information.
| Indication | Induction Phase | Maintenance Phase |
|---|---|---|
| Crohn’s Disease | 600 mg intravenous infusion at Week 0, Week 4, and Week 8. | 360 mg subcutaneous injection at Week 12, then every 8 weeks thereafter. |
| Plaque Psoriasis / Psoriatic Arthritis | 150 mg subcutaneous injection at Week 0 and Week 4. | 150 mg subcutaneous injection every 12 weeks thereafter. |
Switching
The decision to switch a patient to Skyrizi from another biologic agent is a clinical judgment. Factors to consider include the previous therapy’s mechanism of action, the patient’s response and tolerance, and any recommended washout periods. The calculator assumes the “Induction” phase begins on the date of the very first Skyrizi dose, regardless of prior treatments.
Missed Dose
If a patient misses a dose, instruct them to administer it as soon as possible. The subsequent dosing schedule should then be adjusted to maintain the correct interval from the date the missed dose was administered. This tool can be used to recalculate the new maintenance schedule by entering the date of the late dose as the “Date of Last Dose”. Always refer to the full prescribing information for specific guidance.
Safety Alerts
Skyrizi may increase the risk of infections. Evaluate patients for tuberculosis (TB) prior to initiating treatment. The most common adverse reactions include upper respiratory infections, headache, fatigue, injection site reactions, and tinea infections. This calculator does not provide medical advice or account for contraindications or adverse events. Consult the full prescribing information for a complete list of warnings, precautions, and adverse reactions.
FAQ
Tool Functionality
- What happens when I select “Crohn’s Disease” and “Induction”?
The calculator will output a schedule for three 600 mg IV infusions at Week 0, 4, and 8, followed by the first 360 mg SC maintenance dose at Week 12. - What does the calculator show for Psoriasis Maintenance?
After entering the date of the last 150 mg SC dose, the tool projects the dates for the next four maintenance doses, each scheduled 12 weeks apart. - What date should I enter for the “Maintenance” phase?
Enter the date the patient received their most recent maintenance dose to calculate the next set of scheduled dates. - Does the tool store any patient information?
No. As stated in the tool’s footer, it is a client-side calculator and does not store or transmit any personal or patient data.
Clinical Considerations
- Is this tool a substitute for the Prescribing Information?
No. This tool is for educational convenience only and does not replace clinical judgment or the comprehensive guidance provided in the FDA-approved full Prescribing Information. - Why is the maintenance dose and frequency different for CD vs. PsO/PsA?
The dosing regimens were established in separate clinical trial programs to determine the optimal efficacy and safety for each distinct indication. - Can I use this tool for pediatric patients?
This calculator is based on adult dosing regimens. Dosing for pediatric populations may differ. Always consult the specific Prescribing Information for age- and weight-appropriate dosing if available. - Does the tool account for dose adjustments or interruptions?
No. It calculates the standard, uninterrupted dosing schedule. Any deviation from this schedule requires clinical assessment.
References
- SKYRIZI® (risankizumab-rzaa) Full Prescribing Information. U.S. Food and Drug Administration.
- Skyrizi (risankizumab-rzaa) Healthcare Professional Website. AbbVie Inc.
- Drugs@FDA: FDA-Approved Drugs – SKYRIZI (risankizumab-rzaa).
- Gordon KB, et al. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet. 2018.
